CN121949442A - 海兔脯氨酸-海兔异亮氨酸肽的衍生物 - Google Patents

海兔脯氨酸-海兔异亮氨酸肽的衍生物

Info

Publication number
CN121949442A
CN121949442A CN202610089819.2A CN202610089819A CN121949442A CN 121949442 A CN121949442 A CN 121949442A CN 202610089819 A CN202610089819 A CN 202610089819A CN 121949442 A CN121949442 A CN 121949442A
Authority
CN
China
Prior art keywords
methoxy
methyl
amino
dimethylamino
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202610089819.2A
Other languages
English (en)
Chinese (zh)
Inventor
B·A·门德尔松
J·度戈尔-泰西耶
S·D·巴恩彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of CN121949442A publication Critical patent/CN121949442A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202610089819.2A 2014-05-28 2015-05-27 海兔脯氨酸-海兔异亮氨酸肽的衍生物 Pending CN121949442A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462004084P 2014-05-28 2014-05-28
US62/004,084 2014-05-28
PCT/US2015/032704 WO2015183978A1 (en) 2014-05-28 2015-05-27 Derivatives of dolaproine-dolaisoleuine peptides
CN201580041582.0A CN107041139A (zh) 2014-05-28 2015-05-27 海兔脯氨酸‑海兔异亮氨酸肽的衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580041582.0A Division CN107041139A (zh) 2014-05-28 2015-05-27 海兔脯氨酸‑海兔异亮氨酸肽的衍生物

Publications (1)

Publication Number Publication Date
CN121949442A true CN121949442A (zh) 2026-05-01

Family

ID=54699722

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202610089819.2A Pending CN121949442A (zh) 2014-05-28 2015-05-27 海兔脯氨酸-海兔异亮氨酸肽的衍生物
CN201580041582.0A Pending CN107041139A (zh) 2014-05-28 2015-05-27 海兔脯氨酸‑海兔异亮氨酸肽的衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580041582.0A Pending CN107041139A (zh) 2014-05-28 2015-05-27 海兔脯氨酸‑海兔异亮氨酸肽的衍生物

Country Status (9)

Country Link
US (3) US20170190735A1 (https=)
EP (1) EP3149024B9 (https=)
JP (3) JP2017519740A (https=)
KR (1) KR102413079B1 (https=)
CN (2) CN121949442A (https=)
ES (1) ES2883023T3 (https=)
RU (1) RU2747989C2 (https=)
SG (1) SG11201609739UA (https=)
WO (1) WO2015183978A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015183978A1 (en) * 2014-05-28 2015-12-03 Agensys, Inc. Derivatives of dolaproine-dolaisoleuine peptides
WO2017058808A1 (en) * 2015-10-02 2017-04-06 Sirenas Llc Anti-cancer compounds and conjugates thereof
EP4321522A1 (en) * 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
CN120917016A (zh) * 2023-05-06 2025-11-07 荣昌生物制药(烟台)股份有限公司 一种奥瑞他汀衍生物中间体的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003054A1 (fr) * 1991-08-09 1993-02-18 Teikoku Hormone Mfg. Co., Ltd. Nouveau derive de tetrapeptide
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH06234790A (ja) * 1993-02-09 1994-08-23 Teikoku Hormone Mfg Co Ltd 新規テトラペプチドアミド誘導体
EP0731106B1 (en) 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) * 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) * 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US7008928B2 (en) * 2001-09-20 2006-03-07 Teikoku Hormone Mfg. Co., Ltd. Tetrapeptide derivative TZT-1027 crystal
EP1675465B1 (en) 2003-10-22 2010-03-03 The Johns Hopkins University Improved combination bacteriolytic therapy for the treatment of tumors
CA2572318A1 (en) * 2004-07-02 2006-01-12 Neutec Pharma Plc Treatment of cancer
US8288352B2 (en) * 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
CN101242816B (zh) * 2005-06-30 2012-10-31 维罗贝股份有限公司 Hcv抑制剂
ES2708763T3 (es) * 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
CN101932598B (zh) 2008-01-30 2016-12-21 皮里斯股份公司 具有对人c-met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
DK2265283T3 (da) * 2008-03-18 2014-10-20 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
US9120854B2 (en) * 2008-04-11 2015-09-01 Seattle Genetics, Inc. Detection and treatment of pancreatic, ovarian and other cancers
BR112013027119A8 (pt) 2011-04-21 2018-03-06 Seattle Genetics Inc novos conjugados ligante-droga (adcs) e uso dos mesmos
RU2566693C2 (ru) * 2011-07-08 2015-10-27 Сименс Акциенгезелльшафт Система слоев с двухслойным металлическим слоем
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
CN104185477B (zh) * 2011-11-17 2017-05-24 辉瑞公司 细胞毒性肽及其抗体‑药物缀合物
CN104640572B (zh) * 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物，偶联方法，及其用途
KR101763499B1 (ko) * 2012-11-07 2017-07-31 화이자 인코포레이티드 항-il-13 수용체 알파 2 항체 및 항체-약물 접합체
CA2890571A1 (en) 2012-11-07 2014-05-15 Kenneth G. Geles Anti-notch3 antibodies and antibody-drug conjugates
WO2015183978A1 (en) * 2014-05-28 2015-12-03 Agensys, Inc. Derivatives of dolaproine-dolaisoleuine peptides

Also Published As

Publication number Publication date
EP3149024A1 (en) 2017-04-05
EP3149024B1 (en) 2021-05-12
CN107041139A (zh) 2017-08-11
EP3149024A4 (en) 2018-06-06
ES2883023T3 (es) 2021-12-03
RU2016150426A3 (https=) 2018-12-20
WO2015183978A1 (en) 2015-12-03
SG11201609739UA (en) 2016-12-29
JP2022027896A (ja) 2022-02-14
US20200325170A1 (en) 2020-10-15
JP2020128405A (ja) 2020-08-27
JP6995160B2 (ja) 2022-01-14
KR20170005495A (ko) 2017-01-13
JP7292366B2 (ja) 2023-06-16
RU2747989C2 (ru) 2021-05-18
JP2017519740A (ja) 2017-07-20
US20170190735A1 (en) 2017-07-06
RU2016150426A (ru) 2018-07-03
US11312748B2 (en) 2022-04-26
KR102413079B1 (ko) 2022-06-24
US20220204557A1 (en) 2022-06-30
US12612429B2 (en) 2026-04-28
EP3149024B9 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
TWI395746B (zh) 抗病毒性化合物
JP2021535196A (ja) Ｉｌ−２受容体結合化合物
US12612429B2 (en) Derivatives of dolaproine-dolaisoleuine peptides
US20240067616A1 (en) Peptide conjugates of microtubule-targeting agents as therapeutics
JP2021501201A (ja) ステープルペプチドの細胞内送達のためのポリペプチド接合体
JP4903717B2 (ja) トリペプチドおよびテトラペプチドスルホン
CN118414169A (zh) 反式环辛烯缀合物
WO2020230780A1 (ja) Ｒａｓ阻害ペプチド
JP2023544223A (ja) 標的化ｐｅｔ／ｓｐｅｃｔ撮像のための放射性標識リガンド及びそれらの使用方法
WO2021200259A1 (ja) Ｖｉｐｒ２アンタゴニストペプチド
JP7734891B2 (ja) 新規な構造を有するポリペプチド薬物複合体及びその使用
WO2024043249A1 (ja) 環状ペプチドまたはその塩、およびｍｄｍｘ阻害剤
JP7610862B2 (ja) がんの予防または治療用薬学的組成物
CN121419788A (zh) 用于体内递送有效载荷的基于四嗪的靶向剂
WO2023088236A1 (zh) Mt1-mmp的双环肽配体及其缀合物
HK1243085A1 (en) Derivatives of dolaproine-dolaisoleuine peptides
HK40109540A (zh) 反式环辛烯缀合物
WO2022155172A1 (en) Peptide conjugates of therapeutics
WO2025213185A1 (en) Peptide conjugates
WO2026016338A1 (zh) 基于N-degron的新型无连接子的微型PROTAC化合物及其用途
JP2021183605A (ja) Ｉｌ−２受容体結合化合物

Legal Events

Date Code Title Description
PB01 Publication